Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 7 years, with Sep 2025 value amounting to $87.3 million.

  • Iovance Biotherapeutics' Accumulated Expenses was N/A to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year change of. This contributed to the annual value of $81.9 million for FY2024, which is 18.05% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Accumulated Expenses stood at $87.3 million for Q3 2025, which was down 2.04% from $89.1 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Accumulated Expenses high stood at $89.1 million for Q2 2025, and its period low was $43.1 million during Q1 2023.
  • Its 3-year average for Accumulated Expenses is $67.8 million, with a median of $69.4 million in 2023.
  • Data for Iovance Biotherapeutics' Accumulated Expenses shows a peak YoY soared of 82.41% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Accumulated Expenses stood at $69.4 million in 2023, then rose by 18.05% to $81.9 million in 2024, then spiked by 82.41% to $87.3 million in 2025.
  • Its Accumulated Expenses was $87.3 million in Q3 2025, compared to $89.1 million in Q2 2025 and $84.7 million in Q1 2025.